Studying When to Add Biological Therapy to Cytotoxic Therapy in Advanced Cancer Care Using Real World Data: How to Avoid Design Choices That Generate Immortal Time.

Saved in:
Bibliographic Details
Title: Studying When to Add Biological Therapy to Cytotoxic Therapy in Advanced Cancer Care Using Real World Data: How to Avoid Design Choices That Generate Immortal Time.
Authors: Garcia-Albeniz X; RTI Health Solutions, Barcelona, Spain., Vila-Guilera J; RTI Health Solutions, Barcelona, Spain., Zamparini M; RTI Health Solutions, Barcelona, Spain., Oliveres H; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain., Alonso-Orduna V; Medical Oncology Service, Hospital Universitario Miguel Servet, Zaragoza, Spain., Feliu J; Medical Oncology Department, Hospital Universitario La Paz. Instituto de Investigación Hospital Universitario La Paz (IdiPAZ), Universidad Autónoma de Madrid. Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain., Fernández-Montes A; Department of Medical Oncology, Complexo Hospitalario Universitario de Ourense, Ourense, Spain., Martín-Richard M; Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., Gálvez-Munoz E; Medical Oncology, Hospital General Universitario de Elda Virgen de la Salud, Elda, Spain., Ruiz-Casado A; Medical Oncology Department, Hospital Universitario Puerta de Hierro-Majadahonda, IDIPHISA, Majadahonda, Spain., Yubero-Esteban A; Medical Oncology Department, Hospital Clinico Universitario Lozano Blesa, Zaragoza, Spain., Aparicio J; Department of Medical Oncology, Hospital Universitari i Politècnic La Fe, Valencia, Spain., Alcaide-Garcia J; Medical Oncology Department, Hospital Costa del Sol, Marbella. Hospital Regional Universitario de Málaga, IBIMA, Malaga, Spain., Plazas JG; Medical Oncology, Hospital General Universitario de Elche, Elche, Spain., Fernandez-Martos C; Medical Oncology, IVO-Fundación Instituto Valenciano de Oncología, Valencia, Spain., Gallego-Sanchez R; Oncology Department, Hospital General de Granollers, Granollers, Spain., Morales MG; Medical Oncology, Hospital Universitario Son Espases, Palma De Mallorca, Spain., Leno R; Medical Oncology Department, Hospital Virgen Del Puerto, Plasencia, Spain., Esposito F; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain., Lopez-Prades S; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain., Cuatrecasas M; Pathology Department, Hospital Clínic Barcelona, University of Barcelona. August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Dgestivas (CIBERehd), Madrid, Spain., Dickerman BA; CAUSALab, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA., Maurel J; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain.
Source: Cancer medicine [Cancer Med] 2026 Jun; Vol. 15 (6), pp. e71950.
Publication Type: Journal Article
Journal Info: Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN: 2045-7634 (Electronic) Linking ISSN: 20457634 NLM ISO Abbreviation: Cancer Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2045-7634
DOI:10.1002/cam4.71950